Examkin

Question

Difficulty: EasyMonitoring and Treatment Evaluation

A 72-year-old man comes to the clinic to establish care. He was recently diagnosed with paroxysmal atrial fibrillation and was started on apixaban for stroke prophylaxis. Due to highly symptomatic palpitations despite maximum tolerated beta-blocker therapy, the decision is made today to initiate oral amiodarone for rhythm control. He has a history of essential hypertension but no other major medical conditions. Which of the following tests are indicated for baseline and routine ongoing monitoring of this new antiarrhythmic therapy? (Select all that apply)

  1. Thyroid-stimulating hormone (TSH) levelAnswer
  2. Hepatic function panelAnswer
  3. C
    Routine high-resolution computed tomography (HRCT) of the chest
  4. Chest radiograph and pulmonary function testsAnswer
  5. E
    Coagulation profile including prothrombin time and INR

Answer

The required baseline and ongoing monitoring tests for amiodarone therapy include a thyroid-stimulating hormone (TSH) level, a hepatic function panel, and a combination of a chest radiograph and pulmonary function tests.
Amiodarone is a highly effective Class III antiarrhythmic agent but has a complex adverse effect profile due to its high iodine content, lipophilicity, and extensive tissue accumulation. It is well-documented to cause thyroid dysfunction (both hyperthyroidism and hypothyroidism), hepatotoxicity, and potentially fatal pulmonary toxicity (such as interstitial pneumonitis and pulmonary fibrosis). Consequently, standard-of-care guidelines mandate that before initiating therapy, and periodically thereafter, patients must undergo monitoring with a thyroid-stimulating hormone (TSH) level, a hepatic function panel, and a pulmonary evaluation consisting of a chest radiograph and pulmonary function tests (alongside electrocardiograms).

Step-by-Step Solution

1
Identify the prescribed high-risk medication and its organ toxicity profile.
The patient is starting amiodarone, which is known to cause significant thyroid, hepatic, and pulmonary toxicity over time.
Recognizing the broad toxicity profile of amiodarone determines the specific laboratory and diagnostic monitoring parameters required.
2
Select the appropriate guideline-concordant tests for baseline and periodic surveillance.
Standard monitoring protocols mandate baseline and routine evaluation with TFTs, LFTs, a chest radiograph, and PFTs (along with an ECG).
Regular surveillance detects early, asymptomatic organ dysfunction, allowing for timely medication adjustment or discontinuation before irreversible damage occurs.
3
Exclude unnecessary or inappropriate tests based on the patient's presentation and concurrent medication regimen.
Routine HRCT of the chest and a coagulation profile are excluded.
HRCT is indicated only if symptoms of pulmonary toxicity develop. Coagulation monitoring is inappropriate because the patient is taking apixaban, which does not require PT/INR surveillance, unlike warfarin.

Key Concept

Baseline and ongoing monitoring for amiodarone toxicity
Estimated Time:1m 0s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic